K. Yeo

发表

Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach

M. Jamei, A. Rostami-Hodjegan, K. Yeo, 2013, Expert review of clinical pharmacology.

Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers

H. Rong, D. Welty, K. Yeo, 2017, Pediatric Drugs.

Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.

Masoud Jamei, David B Turner, Amin Rostami-Hodjegan, 2013, Journal of pharmaceutical sciences.

Physiologically-Based Pharmacokinetics

M. Jamei, A. Rostami-Hodjegan, A. Darwich, 2011 .

Coronary and cardiovascular risk estimation for primary prevention:validation of a new Sheffield table in the 1995 Scottish health survey population

I. U. Haq, P. Ghahramani, L. Ramsay, 2000, BMJ : British Medical Journal.

Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.

M. Jamei, G. Tucker, A. Rostami-Hodjegan, 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling.

Diansong Zhou, Hongmei Xu, N. Al-Huniti, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.

M. Jamei, G. Tucker, A. Rostami-Hodjegan, 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes

K. Yeo, W. W. Yeo, 2001 .

MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE

G. Tucker, A. Rostami-Hodjegan, A. Heydari, 2004, Drug Metabolism and Disposition.

MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

G. Tucker, A. Rostami-Hodjegan, M. Lennard, 2004 .

PREDICTING THE CLEARANCE OF CYP2C9 SUBSTRATES

G. Tucker, A. Rostami-Hodjegan, E. Howgate, 2004, Drug Metabolism and Disposition.

Misuse of the Well-Stirred Model of Hepatic Drug Clearance

M. Jamei, G. Tucker, A. Rostami-Hodjegan, 2007, Drug Metabolism and Disposition.

Dosing will be a key success factor in repurposing antivirals for COVID‐19

C. Rayner, D. Bentley, Patrick F. Smith, 2020, British journal of clinical pharmacology.

Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro

C. Rayner, G. Dow, K. Yeo, 2020, bioRxiv.

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Masoud Jamei, David B Turner, Amin Rostami-Hodjegan, 2013, Journal of pharmaceutical sciences.

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

Amir Heydari, Masoud Jamei, Amin Rostami-Hodjegan, 2006, Journal of psychopharmacology.

Prediction of intestinal first-pass drug metabolism.

Masoud Jamei, Amin Rostami-Hodjegan, Geoffrey T Tucker, 2007, Current drug metabolism.

The effect of chronic tobacco smoking on arterial stiffness.

C. Beck, K. Yeo, Nirandeep Rehill, 2006, British journal of clinical pharmacology.

Predicting CHD risk in patients with diabetes mellitus

K. Yeo, W. W. Yeo, 2001, Diabetic medicine : a journal of the British Diabetic Association.

Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.

K. Yeo, W. W. Yeo, Karen Rowland Yeo, 2001, British journal of clinical pharmacology.

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.

Masoud Jamei, Amin Rostami-Hodjegan, Geoffrey T Tucker, 2008, Current drug metabolism.

Framework, Organization, and Applications of the Simcyp Population-Based Simulator to Support New Drug Development

Karen Rowland Yeo, Amin Rostami-Hodjegan, A. Rostami-Hodjegan, 2014 .

Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure

Amin Rostami-Hodjegan, A. Rostami-Hodjegan, K. Yeo, 2013, European Journal of Clinical Pharmacology.

Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model

Amin Rostami-Hodjegan, A. Rostami-Hodjegan, E. Howgate, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.

K. Yeo, O. Hatley, Katherine L. Gill, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.

L. Ramsay, K. Yeo, E. Wallis, 1999, British journal of clinical pharmacology.

Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure

A. Rostami-Hodjegan, K. Yeo, J. Kenny, 2013, European Journal of Clinical Pharmacology.

Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations

A. Rostami-Hodjegan, A. Rostami-Hodjegan, M. Lennard, 2010, Biopharmaceutics & drug disposition.

Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability

G. Tucker, A. Rostami-Hodjegan, E. Howgate, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Should we treat high-normal blood pressure?

K. Yeo, W. W. Yeo, 2002, Journal of hypertension.

Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors

A. Rostami-Hodjegan, K. Rowland Yeo, H. Crewe, 2011, Biopharmaceutics & drug disposition.

MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE

G. Tucker, A. Rostami-Hodjegan, A. Heydari, 2004, Drug Metabolism and Disposition.

Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

M. Jamei, R. Walsky, G. Tucker, 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.